| Revenue growth | FY26 India growth 9%; International formulations FY26 growth 2%. |
|---|---|
| Margins | Gross margin improved to 70% from 66% due to product mix. |
| Order book | Sufficient number of new CDMO projects/contracts on hand. |
| Demand visibility | Strong brand equity in chronic/cardiac segments providing visibility. |
| Management confidence | High confidence in branded portfolio acceleration post-integration. |
Growth
Revenue fell 5% to ₹904cr. Branded India business grew 8% in Q4; FY26 India business grew 9% to ₹2,461cr.
Outlook
Expects gradual recovery to double-digit growth in India and single-digit in International; merger with Torrent nearing completion.
Risks
Container constraints in West Asia and Southeast Asia; integration-related temporary slowdown in India and international volumes.
Earnings Call filed with NSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.
JB Chemicals & Pharmaceuticals Q4 FY26 Results: Net Profit ₹101.4 Cr, Down 30.4% YoY
JB Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹904.2 Cr (-4.8% YoY) and net profit of ₹101.4 Cr (-30.4% YoY) for Q4 FY26.
- Key figure
- Net profit ₹101.4 Cr · -30.4% YoY